Literature DB >> 10715043

Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions.

T Livraghi1, S N Goldberg, S Lazzaroni, F Meloni, T Ierace, L Solbiati, G S Gazelle.   

Abstract

PURPOSE: To study local therapeutic efficacy, side effects, and complications of radio-frequency (RF) ablation in the treatment of medium and large hepatocellular carcinoma (HCC) lesions in patients with cirrhosis or chronic hepatitis.
MATERIALS AND METHODS: One-hundred fourteen patients who were under conscious sedation or general anesthesia had 126 HCCs greater than 3.0 cm in diameter treated with RF by using an internally cooled electrode. Eighty tumors were medium (3.1-5.0 cm), and 46 were large (5.1-9.5 cm). The mean diameter for all tumors was 5.4 cm. At imaging, 75 tumors were considered noninfiltrating, and 51 were considered infiltrating.
RESULTS: Complete necrosis was attained in 60 lesions (47.6%), nearly complete (90%-99%) necrosis in 40 lesions (31.7%), and partial (50%-89%) necrosis in the remaining 26 lesions (20.6%). Medium and/or noninfiltrating tumors were treated successfully significantly more often than large and/or infiltrating tumors. Two major complications (death, hemorrhage requiring laparotomy) and five minor complications (self-limited hemorrhage, persistent pain) were observed. The single death was due to a break in sterile technique rather than to the RF procedure itself.
CONCLUSION: RF ablation appears to be an effective, safe, and relatively simple procedure for the treatment of medium and large HCCs.

Entities:  

Mesh:

Year:  2000        PMID: 10715043     DOI: 10.1148/radiology.214.3.r00mr02761

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  229 in total

Review 1.  Ablative therapy for liver tumours.

Authors:  E A Dick; S D Taylor-Robinson; H C Thomas; W M W Gedroyc
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

Review 2.  Complications after percutaneous ablation of liver tumors: a systematic review.

Authors:  Eylon Lahat; Rony Eshkenazy; Alex Zendel; Barak Bar Zakai; Mayan Maor; Yael Dreznik; Arie Ariche
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

Review 3.  Principles of and advances in percutaneous ablation.

Authors:  Muneeb Ahmed; Christopher L Brace; Fred T Lee; S Nahum Goldberg
Journal:  Radiology       Date:  2011-02       Impact factor: 11.105

4.  Radiofrequency ablation treatment in proximity to the gallbladder without subsequent acute cholecystitis.

Authors:  Jay W Patti; Ziv Neeman; Bradford J Wood
Journal:  Cardiovasc Intervent Radiol       Date:  2003 Jul-Aug       Impact factor: 2.740

Review 5.  Treatment strategies for hepatocellular carcinoma in cirrhosis.

Authors:  W Scott Helton; Adrian Di Bisceglie; Ravi Chari; Myron Schwartz; Jordi Bruix
Journal:  J Gastrointest Surg       Date:  2003 Mar-Apr       Impact factor: 3.452

6.  Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.

Authors:  S D Ryder
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

7.  Bipolar radiofrequency ablation in ex vivo bovine liver with the open-perfused system versus the cooled-wet system.

Authors:  Jeong Min Lee; Joon Koo Han; Se Hyung Kim; Kyu Li Sohn; Seung Hong Choi; Byung Ihn Choi
Journal:  Eur Radiol       Date:  2004-07-10       Impact factor: 5.315

Review 8.  Role of interventional radiology in managing pediatric liver tumors : Part 2: percutaneous interventions.

Authors:  C Matthew Hawkins; Alexander J Towbin; Derek J Roebuck; Eric J Monroe; Anne E Gill; Avnesh S Thakor; Richard B Towbin; Anne Marie Cahill; Matthew P Lungren
Journal:  Pediatr Radiol       Date:  2018-02-02

Review 9.  Combined interventional therapies of hepatocellular carcinoma.

Authors:  Jun Qian; Gan-Sheng Feng; Thomas Vogl
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

Review 10.  Combining locoregional therapies in the treatment of hepatocellular carcinoma.

Authors:  Mikhail C S S Higgins; Michael C Soulen
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.